Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026
Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026
Same author

New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.

Blood cancer discovery·2026
Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026
Same author

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.

American journal of hematology·2026
Same author

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nature communications·2026
Same journal

A timeseries analysis of the fracture callus extracellular matrix proteome during bone fracture healing.

Journal of life sciences (Westlake Village, Calif.)·2022
Same journal

The role of wild-type tau in Alzheimer's disease and related tauopathies.

Journal of life sciences (Westlake Village, Calif.)·2021
Same journal

Integration of spatial and non-spatial information by heterogeneous dentate gyrus granule cells.

Journal of life sciences (Westlake Village, Calif.)·2021
Same journal

Modulating lysosomal pH: a molecular and nanoscale materials design perspective.

Journal of life sciences (Westlake Village, Calif.)·2021
Same journal

T cell receptor sequencing in autoimmunity.

Journal of life sciences (Westlake Village, Calif.)·2020
Same journal

Mitochondrial respiratory chain composition and organization in response to changing oxygen levels.

Journal of life sciences (Westlake Village, Calif.)·2020
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K

Immunotherapy for hematological malignancies.

Shuai Dong1, Irene M Ghobrial1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA Harvard Institute of Medicine Room 237, 4 Blackfan Circle, Boston MA 02115.

Journal of Life Sciences (Westlake Village, Calif.)
|August 28, 2019
PubMed
Summary
This summary is machine-generated.

Tumor immune tolerance hinders cancer therapy. This review explores immunotherapies like CAR-T cells for hematological cancers, discussing their history, current use, and future potential.

Keywords:
CAR-T cellsCancerImmunotherapyhematological malignancies

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy
05:24

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy

Published on: January 10, 2025

761

Related Experiment Videos

Last Updated: Jan 20, 2026

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy
05:24

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy

Published on: January 10, 2025

761

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Tumor immune tolerance presents a significant obstacle to successful anti-cancer treatments.
  • Solid tumors employ various mechanisms to evade immune surveillance, prompting research into novel therapeutic strategies.
  • Recent advancements have spurred the development of immunotherapies, particularly for hematological malignancies.

Purpose of the Study:

  • To discuss the unique immunological aspects of hematological malignancies.
  • To review the historical development of immunotherapies for blood cancers.
  • To examine the current landscape and future directions of immunotherapy in treating hematological cancers.

Main Methods:

  • Literature review of existing research on tumor immunology and cancer hallmarks.
  • Analysis of treatment strategies for hematological cancers, including chimeric antigen receptor T cells (CAR-T cells) and immune checkpoint inhibitors.
  • Discussion of the distinct characteristics of hematological malignancies influencing immunotherapy response.

Main Results:

  • Immunotherapies have shown significant promise and success in treating certain hematological cancers.
  • Despite advancements, challenges remain in optimizing immunotherapy efficacy for all patients with blood cancers.
  • The unique nature of hematological malignancies necessitates tailored immunotherapeutic approaches.

Conclusions:

  • Hematological cancers present unique challenges and opportunities for immunotherapy.
  • Continued research into the tumor microenvironment and immune evasion mechanisms is crucial.
  • Future directions include refining existing therapies and exploring novel immunotherapeutic strategies for improved patient outcomes.